BioCardia, Inc. — fact timeline

BioCardia, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“April 10, 2026, BioCardia, Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the Company’s stockholders’ equity of $895,000 as of December 31, 2025, it is no longer in compliance with the minimum stockholders’ equity requirement of $2.5 million for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1). The Company has until May 25, 2026 to provide Nasdaq with a plan to regain compliance with the foregoing listing requirement. If the Company’s plan to regain compliance is acc”

BioCardia, Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).

“April 1, 2025, BioCardia, Inc. (the “Company,” “we,” “us” and “our”) received a notification letter (the “Notice”) from the Nasdaq Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that its amount of stockholders’ equity had fallen below the $2,500,000 required minimum for continued listing set forth in Nasdaq Listing Rule 5550(b)(1). As noted in the Original 8-K, the Company had until May 16, 2025 to provide Nasdaq with a specific plan to achieve and sustain compliance. The Company submitted its plan to regain compliance on May 15, 2025”

BioCardia, Inc. reported first quarter of 2024 results: revenue approximately $55,000.

“Revenues were approximately $55,000 for the three months ended March 2024, compared to approximately $64,000 for the three months ended March 2023.”

BioCardia, Inc. reported financial results for the year ended December 31, 2023.

“On March 27, 2024, BioCardia, Inc. issued a press release announcing its financial results for the year ended December 31, 2023.”

BioCardia, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“September 13, 2023, the Company received a separate written notice (the “Minimum Bid-Price Notice”) from Nasdaq, indicating that the Company was no longer in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Minimum Bid-Price Notice provided that, in accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company would have an initial period of 180 calendar days, or until March 11, 2024 (the “Minimum Bid Price Compliance Date”), to regain compliance with”

BioCardia, Inc. received a nasdaq hearing update notice regarding market value (rules 5550(b)(2)).

“March 12, 2024. Additionally, as previously disclosed on a Current Report on Form 8-K filed with the SEC on September 15, 2023, on September 13, 2023, the Company received a separate written notice (the “Minimum Bid-Price Notice”) from Nasdaq, indicating that the Company was no longer in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Minimum Bid-Price Notice provided that, in accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company would have an”

BioCardia, Inc. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).

“on September 13, 2023, the Company received a separate written notice (the “Minimum Bid-Price Notice”) from Nasdaq, indicating that the Company was no longer in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Minimum Bid-Price Notice provided that, in accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company would have an initial period of 180 calendar days, or until March 11, 2024 (the “Minimum Bid Price Compliance Date”), to regain compliance w”